| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| CM-24 | CM-24 (MK-6018); MK-6018; CM-24 | Phase 2 Clinical | Merck Sharp & Dohme Corp | Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Melanoma; Ovarian Neoplasms; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms; Thyroid Cancer, Papillary; Urinary Bladder Neoplasms | Details |